Related Experiment Video
Updated: Jun 4, 2025
06:08
Transcranial Pulse Stimulation for Alzheimer's Patients
Published on: April 4, 2025
408
Apathy Associated with Alzheimer's Disease.
Dan Wu1,2, Bo Zhang1, Yajuan Chang1
1Institute of Chinese Medicine, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
Current Alzheimer Research
|December 24, 2024
Summary
Apathy in Alzheimer's disease (AD) is complex and often underestimated. Understanding its neurobiology is key to developing effective multimodal treatments combining medication and personalized therapies.
Area of Science:
- Neuroscience
- Neurology
- Psychiatry
Background:
- Apathy is a primary neuropsychiatric symptom in Alzheimer's disease (AD).
- Apathy in AD is frequently underestimated despite its prevalence and impact.
- It presents as a complex, multidimensional condition requiring thorough investigation.
Purpose of the Study:
- To systematically review the literature on apathy in Alzheimer's disease.
- To explore the neurobiological, neurochemical, and behavioral characteristics of apathy in AD.
- To identify potential therapeutic strategies for managing apathy in AD patients.
Main Methods:
- Conducted a systematic literature review using PubMed, Scopus, and Web of Science.
- Included studies published within the last 10 years, focusing on neurobiology, neurochemistry, and behavior.
- Screened articles by title, abstract, and full-text review based on pre-defined inclusion criteria.
Main Results:
- Research highlights the front-striatal circuitry, including the anterior cingulate cortex (ACC), in apathy.
- Reviewed neurochemical, neuropsychological, and neuropathological factors associated with apathy symptoms.
- Identified key characteristics contributing to apathy in Alzheimer's disease.
Conclusions:
- Understanding the neurobiological basis of apathy in AD is essential for targeted interventions.
- A multimodal treatment approach combining pharmacological and non-pharmacological strategies is recommended.
- Further research into combined therapeutic modalities is needed to improve patient outcomes.
Keywords:
Alzheimer’s diseaseanterior cingulate cortexapathybehaviorologyneuropsychiatrictherapeutic efficacy.More Related Videos
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.8K
Related Concept Videos
01:26Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
01:22Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162
01:30Negative and Cognitive Symptoms of Schizophrenia
43
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
43
01:15Parkinson's Disease: Overview
476
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
476
01:30Dementia
94
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
94
01:24Parkinson's Disease: Treatment
216
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
216